Advancing science to conquer cancer
Translating research into innovative therapeutics
Multiple therapies to help cancer patients
Curing Cancer
From discovery to development
Leading innovation with a robust pipeline
Focused therapeutics for oncology
Our story
Founded in 2002, we are a clinical stage biotech company committed to the discovery and development of novel and effective therapeutics for the treatment of cancer.
We leverage our deep expertise in oncology focused novel therapeutics for the benefit of cancer patients everywhere.
Our story
Founded in 2002, we are a clinical stage biotech company committed to the discovery and development of novel and effective therapeutics for the treatment of cancer.
We leverage our deep expertise in oncology focused novel therapeutics for the benefit of cancer patients everywhere.
Video of our Journey
Play Video
Our approach
We focus on developing innovative therapeutics addressing several hallmarks of cancer, leveraging our deep capabilities in science and building value added collaborations with leading companies globally.
Our impact
We have built comprehensive drug discovery and development capabilities, nurtured a growing team of passionate scientists, and collaborated with partners from across the world.
Two decades of drug discovery and development experience
80+
integrated drug discovery projects
20
programs in global clinical development
450+
scientists
200+
NCE patents
Media center
Get the latest updates from Aurigene in the news, conferences, events, and more.
July 5, 2022
Aurigene Discovery Technologies Limited Announces Drug Discovery, Development, and Commercialization Partnership with EQRx
June 9, 2022
Olema Oncology and Aurigene Announce Exclusive Collaboration and License Agreement to Discover and Develop Novel Cancer Therapies
Our publications
Explore our vast body of work in oncology research, innovative technology and therapeutics.
SMARCA2/4 degraders relieve the differentiation block in AML via changes in chromatin looping...
Targeting the SWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies